190 related articles for article (PubMed ID: 12554804)
1. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3.
Gao P; Zhou XY; Yashiro-Ohtani Y; Yang YF; Sugimoto N; Ono S; Nakanishi T; Obika S; Imanishi T; Egawa T; Nagasawa T; Fujiwara H; Hamaoka T
J Leukoc Biol; 2003 Feb; 73(2):273-80. PubMed ID: 12554804
[TBL] [Abstract][Full Text] [Related]
2. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis.
Tokuyama H; Ueha S; Kurachi M; Matsushima K; Moriyasu F; Blumberg RS; Kakimi K
Int Immunol; 2005 Aug; 17(8):1023-34. PubMed ID: 16000328
[TBL] [Abstract][Full Text] [Related]
3. Chemokine receptor blockade with a synthetic nonpeptide compound attenuates cardiac allograft vasculopathy.
Bastani S; Sherman W; Schnickel GT; Hsieh GR; Bhatia R; Fishbein MC; Ardehali A
Transplantation; 2009 Oct; 88(8):995-1001. PubMed ID: 19855245
[TBL] [Abstract][Full Text] [Related]
4. A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation.
Suzaki Y; Hamada K; Nomi T; Ito T; Sho M; Kai Y; Nakajima Y; Kimura H
Eur Respir J; 2008 Apr; 31(4):783-9. PubMed ID: 18094012
[TBL] [Abstract][Full Text] [Related]
5. CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779.
Nedjai B; Viney JM; Li H; Hull C; Anderson CA; Horie T; Horuk R; Vaidehi N; Pease JE
Br J Pharmacol; 2015 Apr; 172(7):1822-33. PubMed ID: 25425280
[TBL] [Abstract][Full Text] [Related]
6. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection.
Akashi S; Sho M; Kashizuka H; Hamada K; Ikeda N; Kuzumoto Y; Tsurui Y; Nomi T; Mizuno T; Kanehiro H; Hisanaga M; Ko S; Nakajima Y
Transplantation; 2005 Aug; 80(3):378-84. PubMed ID: 16082334
[TBL] [Abstract][Full Text] [Related]
7. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.
Ni J; Zhu YN; Zhong XG; Ding Y; Hou LF; Tong XK; Tang W; Ono S; Yang YF; Zuo JP
Br J Pharmacol; 2009 Dec; 158(8):2046-56. PubMed ID: 20050195
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
Shiraishi M; Aramaki Y; Seto M; Imoto H; Nishikawa Y; Kanzaki N; Okamoto M; Sawada H; Nishimura O; Baba M; Fujino M
J Med Chem; 2000 May; 43(10):2049-63. PubMed ID: 10821717
[TBL] [Abstract][Full Text] [Related]
9. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.
Hall SE; Mao A; Nicolaidou V; Finelli M; Wise EL; Nedjai B; Kanjanapangka J; Harirchian P; Chen D; Selchau V; Ribeiro S; Schyler S; Pease JE; Horuk R; Vaidehi N
Mol Pharmacol; 2009 Jun; 75(6):1325-36. PubMed ID: 19297521
[TBL] [Abstract][Full Text] [Related]
10. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
[TBL] [Abstract][Full Text] [Related]
11. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
[TBL] [Abstract][Full Text] [Related]
12. Chemoattraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines.
Cockwell P; Calderwood JW; Brooks CJ; Chakravorty SJ; Savage CO
Nephrol Dial Transplant; 2002 May; 17(5):734-44. PubMed ID: 11981057
[TBL] [Abstract][Full Text] [Related]
13. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.
van Wanrooij EJ; Happé H; Hauer AD; de Vos P; Imanishi T; Fujiwara H; van Berkel TJ; Kuiper J
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2642-7. PubMed ID: 16239591
[TBL] [Abstract][Full Text] [Related]
14. Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model.
Takama Y; Miyagawa S; Yamamoto A; Firdawes S; Ueno T; Ihara Y; Kondo A; Matsunami K; Otsuka H; Fukuzawa M
Transpl Immunol; 2011 Jul; 25(1):49-55. PubMed ID: 21515370
[TBL] [Abstract][Full Text] [Related]
15. C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential.
Andrew DP; Ruffing N; Kim CH; Miao W; Heath H; Li Y; Murphy K; Campbell JJ; Butcher EC; Wu L
J Immunol; 2001 Jan; 166(1):103-11. PubMed ID: 11123282
[TBL] [Abstract][Full Text] [Related]
16. Blockade of Th1 chemokine receptors ameliorates pulmonary granulomatosis in mice.
Kishi J; Nishioka Y; Kuwahara T; Kakiuchi S; Azuma M; Aono Y; Makino H; Kinoshita K; Kishi M; Batmunkh R; Uehara H; Izumi K; Sone S
Eur Respir J; 2011 Aug; 38(2):415-24. PubMed ID: 21273392
[TBL] [Abstract][Full Text] [Related]
17. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation.
Xie JH; Nomura N; Lu M; Chen SL; Koch GE; Weng Y; Rosa R; Di Salvo J; Mudgett J; Peterson LB; Wicker LS; DeMartino JA
J Leukoc Biol; 2003 Jun; 73(6):771-80. PubMed ID: 12773510
[TBL] [Abstract][Full Text] [Related]
18. Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors.
Verzijl D; Storelli S; Scholten DJ; Bosch L; Reinhart TA; Streblow DN; Tensen CP; Fitzsimons CP; Zaman GJ; Pease JE; de Esch IJ; Smit MJ; Leurs R
J Pharmacol Exp Ther; 2008 May; 325(2):544-55. PubMed ID: 18270317
[TBL] [Abstract][Full Text] [Related]
19. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo.
Stanford MM; Issekutz TB
J Leukoc Biol; 2003 Nov; 74(5):791-9. PubMed ID: 12960247
[TBL] [Abstract][Full Text] [Related]
20. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists.
Sohy D; Yano H; de Nadai P; Urizar E; Guillabert A; Javitch JA; Parmentier M; Springael JY
J Biol Chem; 2009 Nov; 284(45):31270-9. PubMed ID: 19758998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
